Start Submission Become a Reviewer

Reading: The Health Impact Fund: How Might It Work for Novel Anticoagulants in Atrial Fibrillation?

Download

A- A+
Alt. Display

Innovations and Concepts

The Health Impact Fund: How Might It Work for Novel Anticoagulants in Atrial Fibrillation?

Authors:

Amitava Banerjee ,

Centre for Cardiovascular Sciences, College of Medical and Dental Sciences, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, GB
X close

Thomas Pogge

Department of Philosophy, Yale University, New Haven, CT, US
X close

Abstract

Cardiovascular diseases represent the greatest burden of global disease. Spending on cardiovascular diseases is higher than for other diseases, with the majority being spent on drugs. Therefore, these drugs and these diseases are hugely important to health systems, society, and pharmaceutical companies. The Health Impact Fund represents a new mechanism by which pharmaceutical innovators would be rewarded on the basis of the health impact of their new drugs. This review illustrates the concept of the Health Impact Fund using the example of novel anticoagulants for prevention of stroke and thromboembolism in atrial fibrillation. By considering existing data and the current situation for novel anticoagulants, we suggest that epidemiologic data and modeling techniques can be used to predict future trends in disease and the health impact of new drugs. The Health Impact Fund may offer potential benefits to pharmaceutical companies, patients, and governments and warrants proper investigation.

How to Cite: Banerjee A, Pogge T. The Health Impact Fund: How Might It Work for Novel Anticoagulants in Atrial Fibrillation?. Global Heart. 2014;9(2):255–61. DOI: http://doi.org/10.1016/j.gheart.2014.01.005
4
Views
4
Downloads
2
Citations
Published on 01 Jun 2014.
Peer Reviewed

Downloads

  • PDF (EN)

    comments powered by Disqus